Search results for "Cerebral hemorrhage"

showing 10 items of 88 documents

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.

2017

BackgroundIdarucizumab is a monoclonal antibody fragment with high affinity for dabigatran that reverses its anticoagulant effects within minutes. It may exhibit the potential for patients under dabigatran therapy suffering ischemic stroke to regain eligibility for thrombolysis with rt-PA and may inhibit lesion growth in patients with intracerebral hemorrhage on dabigatran.AimsTo provide insights into the clinical use of idarucizumab in patients under effective dabigatran anticoagulation presenting with signs of ischemic stroke or intracranial hemorrhage.MethodsRetrospective data collected from German neurological/neurosurgical departments administering idarucizumab following product launch…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMedizin030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedAntithrombinsDabigatranBrain Ischemia03 medical and health sciences0302 clinical medicineHematomaGermanymedicineHumansThrombolytic TherapyStrokeAgedRetrospective StudiesIntracerebral hemorrhagebusiness.industryAnticoagulantWarfarinIdarucizumabThrombolysismedicine.diseaseSurgeryDabigatranStrokeNeurologyAnesthesiaTissue Plasminogen ActivatorFemalebusinessIntracranial Hemorrhages030217 neurology & neurosurgerymedicine.drugInternational journal of stroke : official journal of the International Stroke Society
researchProduct

Intracerebral Hemorrhage and Outcome After Thrombolysis in Stroke Patients Using Selective Serotonin-Reuptake Inhibitors.

2017

Background and Purpose— Selective serotonin-reuptake inhibitors (SSRIs) impair platelet function and have been linked to a higher risk of spontaneous intracerebral hemorrhage—an association that may be augmented by oral anticoagulants (OAC). We aimed to assess whether preadmission treatment with SSRIs in patients with acute ischemic stroke is associated with post-thrombolysis symptomatic intracerebral hemorrhage (sICH) and functional outcome. Methods— A multicenter retrospective analysis was conducted in prospective registries of patients treated by thrombolysis within 4.5 hours of stroke onset. The association between preadmission treatment with SSRIs and sICH (ECASS II definition [Europe…

Malemedicine.medical_specialtytherapeutic use [Anticoagulants]medicine.medical_treatmentSubgroup analysisepidemiology [Cerebral Hemorrhage]Risk AssessmentCohort Studies03 medical and health sciencesadverse effects [Serotonin Uptake Inhibitors]0302 clinical medicineModified Rankin ScaleInternal medicinemedicineHumansThrombolytic Therapy030212 general & internal medicineddc:610610 Medicine & healthStrokeCerebral HemorrhageAgedRetrospective StudiesAdvanced and Specialized NursingIntracerebral hemorrhageAged 80 and overtherapy [Cerebral Hemorrhage]business.industryAnticoagulantsThrombolysisOdds ratioMiddle Agedmedicine.diseaseadverse effects [Selective Serotonin Reuptake Inhibitors]Prognosisdrug therapy [Stroke]StrokeTreatment OutcomeAnesthesiaConcomitantSerotonin Uptake InhibitorsFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgerySelective Serotonin Reuptake Inhibitorsepidemiology [Stroke]Cohort study
researchProduct

Sevoflurane Impairs Cerebral Blood Flow Autoregulation in Rats: Reversal by Nonselective Nitric Oxide Synthase Inhibition

2005

UNLABELLED In this study, we investigated the effects of 1.0 and 2.0 minimum alveolar anesthetic concentration (MAC) sevoflurane on cerebral blood flow (CBF) autoregulation before and after nonselective inhibition of nitric oxide (NO) synthase in rats. Rats were randomly assigned as follows: Group 1 (n = 8): 1.0 MAC sevoflurane; Groups 2 and 3 (n = 8 per group): 2.0 MAC sevoflurane. Assessment of autoregulation within a mean arterial blood pressure range of 140-60 mm Hg was performed by graded hemorrhage before and after administration of l-arginine methyl ester (l-NAME, 30 mg/kg IV, Groups 1 and 2) or during hypocapnia (Group 3). In 10 additional animals, brain tissue NO(2)(-) concentratio…

Methyl EthersBlood PressureVasodilationPharmacologyNitric OxideSevofluraneNitric oxideRats Sprague-DawleySevofluranechemistry.chemical_compoundHypocapniaAnimalsHomeostasisHyperventilationMedicineAutoregulationEnzyme InhibitorsCerebral HemorrhageBrain ChemistryBlood VolumeDose-Response Relationship Drugbiologybusiness.industrymedicine.diseaseRatsNitric oxide synthaseNG-Nitroarginine Methyl EsterAnesthesiology and Pain MedicineCerebral blood flowchemistryCerebrovascular CirculationAnesthesiaAnesthetics InhalationAnestheticbiology.proteinNitric Oxide Synthasebusinessmedicine.drugAnesthesia & Analgesia
researchProduct

Neuroprotection by erythropoietin and darbopoietin-alfa following experimental intracerebral hemorrhage

2008

Neuroprotection intracerebral hemorrhageSettore MED/27 - Neurochirurgia
researchProduct

Cerebral microbleeds and vascular cognitive impairment

2010

Abstract MRI manifestations of small vessel diseases including white matter hyperintensities and lacunes have been recognized as potential substrates of vascular cognitive impairment for many years. Cerebral microbleeds (CMBs) – small, perviascular haemorrhages seen as small, well-demarcated, hypointense, rounded lesions on MRI sequences sensitive to magnetic susceptibility effects – are also now recognized as an imaging marker for small vessel pathology, but their clinical impact on cognition remains uncertain. CMBs are present in about a third of patients with ischaemic stroke, and in a high proportion of patients with Alzheimer's disease, cerebral amyloid angiopathy, and vascular dementi…

Pathologymedicine.medical_specialtybusiness.industryVascular diseaseDementia VascularCognitive disordermedicine.diseasecerebral microbleeds vascular cognitive impairmentMagnetic Resonance ImagingHyperintensityCentral nervous system diseaseDegenerative diseaseNeurologyHumansMedicineDementiaNeurology (clinical)Cerebral amyloid angiopathyCognition DisordersbusinessVascular dementiaCerebral Hemorrhage
researchProduct

Neurological complications in pediatric patients with SARS-CoV-2 infection: a systematic review of the literature

2021

Abstract Objectives To describe clinical characteristics, laboratory tests, radiological data and outcome of pediatric cases with SARS-CoV-2 infection complicated by neurological involvement. Study design A computerized search was conducted using PubMed. An article was considered eligible if it reported data on pediatric patient(s) with neurological involvement related to SARS-CoV-2 infection. We also described a case of an acute disseminated encephalomyelitis (ADEM) in a 5-year-old girl with SARS-CoV-2 infection: this case was also included in the systematic review. Results Forty-four articles reporting 59 cases of neurological manifestations in pediatric patients were included in our revi…

Pediatricsmedicine.medical_specialtySubarachnoid hemorrhagePneumonia ViralContext (language use)ReviewPediatricsRJ1-570Transverse myelitismedicineHumansChildNervous System DiseaseAutoimmune encephalitisIntracerebral hemorrhageSARS-CoV-2business.industryCranial nervesCOVID-19MeningoencephalitisGeneral Medicinemedicine.diseaseSARS-CoV-2.Acute disseminated encephalomyelitisNervous System DiseasesbusinessHumanItalian Journal of Pediatrics
researchProduct

Comparative analysis of fibrinolytic properties of Alteplase, Tenecteplase and Urokinase in an in vitro clot model of intracerebral haemorrhage.

2020

Abstract Objective Hematoma lysis with recombinant tissue plasminogen activator (rtPA) has emerged as an alternative therapy for spontaneous intracerebral and intraventricular haemorrhage (ICH and IVH). However, the MISTIE III and CLEAR III trial failed to show significant improvement of favourable outcomes. Besides experimental and clinical trials revealed neurotoxic effects of rtPA. The demand for optimization of fibrinolytic therapy persists. Herein, we used our recently devised clot model of ICH to systematically analyse fibrinolytic properties of rtPA, tenecteplase and urokinase. Methods In vitro clots of human blood (size: 25 ml and 50 ml; age: 1.5 tenecteplase, 24 tenecteplase and 48…

Time FactorsTenecteplase03 medical and health sciences0302 clinical medicineHematomaFibrinolytic AgentsmedicineHumansThrombolytic TherapyCerebral HemorrhageUrokinaseHuman bloodDose-Response Relationship Drugbusiness.industryOptimal treatmentFibrinolysisRehabilitationmedicine.diseaseUrokinase-Type Plasminogen ActivatorIn vitroCatheterAnesthesiaTissue Plasminogen ActivatorTenecteplaseSurgeryNeurology (clinical)Fibrinolytic therapyCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgerymedicine.drugJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
researchProduct

Fatal cerebellar haemorrhage due to phenprocoumon poisoning.

1996

A 32-year-old patient died of a cerebellar haemorrhage and the blood coagulation analysis before death suggested defective synthesis of vitamin K-dependent clotting factors due to vitamin K deficiency. The post-mortem toxicological examination of different tissues revealed phenprocoumon poisoning as the cause of death. The differential diagnosis of vitamin K deficiency and the toxicology of hydroxycoumarins are discussed.

VitaminAdultMalemedicine.medical_specialtyBrain DeathPoison controlGastroenterologyPathology and Forensic MedicinePhenprocoumonchemistry.chemical_compoundCerebellar DiseasesInternal medicineVitamin K deficiencyMedicineHumansCause of deathCerebral HemorrhageClotting factorDose-Response Relationship Drugbusiness.industryWarfarinBrainmedicine.diseaseSurgerychemistryPhenprocoumonVitamin K DeficiencyBlood Coagulation TestsDifferential diagnosisDrug Overdosebusinessmedicine.drugInternational journal of legal medicine
researchProduct

A Neurosurgical Stratagem: Doing the Same with Less?

2017

business.industrySettore MED/27 - Neurochirurgiamedicine.disease030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineText miningMedicineSurgeryNeurology (clinical)Medical emergencyIntracerebral hemorrhagebusiness030217 neurology & neurosurgery
researchProduct

Autologous fibrin sealant (Vivostat(®)) in the neurosurgical practice: Part I: Intracranial surgical procedure.

2014

Background: Hemorrhages, cerebrospinal fluid (CSF) fistula and infections are the most challenging postoperative complications in Neurosurgery. In this study, we report our preliminary results using a fully autologous fibrin sealant agent, the Vivostat ® system, in achieving hemostasis and CSF leakage repair during cranio‑cerebral procedures. Methods: From January 2012 to March 2014, 77 patients were studied prospectively and data were collected and analyzed. Autologous fibrin sealant, taken from patient’s blood, was prepared with the Vivostat ® system and applied on the resection bed or above the dura mater to achieve hemostasis and dural sealing. The surgical technique, time to bleeding c…

cerebrospinal fistulamedicine.medical_specialtyDura materFistuladura materAutologous fibrin glue; Cerebral hemorrhage; Cerebrospinal fistula; Dura mater; Skull base copyright; Surgery; Neurology (clinical)FibrinCerebrospinal fluidmedicineFibrin gluecerebral hemorrhagebiologybusiness.industrySkull base copyrightSettore MED/27 - NeurochirurgiaSealantskull basemedicine.diseaseSurgerymedicine.anatomical_structureHemostasisbiology.proteinAutologous fibrin glueSurgeryOriginal ArticleNeurosurgeryNeurology (clinical)businessSurgical neurology international
researchProduct